Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience

Pediatr Neonatol. 2024 Jan;65(1):85-86. doi: 10.1016/j.pedneo.2023.10.002. Epub 2023 Nov 7.

Authors

Yi-Lun Wang¹, Tsung-Yen Chang¹, Yu-Chuan Wen², Shu-Ho Yang², Yi-Wen Hsiao², Shih-Hsiang Chen¹, Tang-Her Jaing³

Affiliations

¹ Division of Hematology/Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
² Department of Nursing, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
³ Division of Hematology/Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan. Electronic address: jaing001@cgmh.org.tw.

PMID: 37951828
DOI: 10.1016/j.pedneo.2023.10.002

No abstract available

MeSH terms

Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / etiology
Hematopoietic Stem Cell Transplantation*
Humans
Nitriles
Pyrazoles*
Pyrimidines*
Retrospective Studies
Steroids

Substances

ruxolitinib
Steroids
Nitriles
Pyrazoles
Pyrimidines